A clinical case demonstrates the potential of transabdominal ultrasound of the large intestine in diagnosis and follow-up in a patient with ulcerative colitis. It is shown that transabdominal ultrasound examination performed in seroscan mode (B-mode) with the use of Doppler color mapping allows to monitor the degree of resolution of inflammation in the mucosa of the large bowel, as well as to evaluate the effectiveness of conservative approach.

Psoriasis is one of the most common chronic immune-mediated skin diseases. One of the widely discussed gastroenterological comorbidities of psoriasis is chronic inflammatory diseases of the gastrointestinal tract. The article presents the results of the analysis of the case histories of patients with moderate-to-severe and severe forms of psoriasis and concomitant pathology – inflammatory bowel diseases (Clinical Dermatovenerologic Dispensary, Krasnodar, Russia). The analysis of 16 case histories of patients with moderate-to-severe and severe psoriasis has been carried out, where one can see the clinical and practical significance of the combined pathology – psoriasis and inflammatory bowel diseases. From the analysis, one can conclude that there is a direct relationship between the severity of the course of the skin pathological process and the development of intestinal diseases, as well as the influence of ustekinumab on the course of combined pathology – psoriasis, ulcerative colitis and Crohn’s disease.

The article presents the results of clinical studies and real practice of the effectiveness and safety of the use of a new genetically engineered biological drug Risankizumab. Skyrizi (risankizumab) is an innovative drug, it is a humanized monoclonal antibody – immunoglobulin class G1 (IgG1) – which specifcally inhibits the cytokine IL-23 by binding to its subunit p19. It is believed that cytokine IL-23, involved in inflammatory processes, is associated with a number of chronic immune-mediated diseases, including psoriasis. According to direct comparative randomized clinical trials, risankizumab is superior in effectiveness in the short term and, most importantly, in the long term most genetically engineered biologic drugs, including TNF-α inhibitors, secukinumab, ustekinumab. In the ultIMMa-1 and ultIMMa-2 studies, sPGA 0/1 and PASI 90 (p < 0.001) were achieved after 16 weeks of treatment with Skyrizi. After 16 weeks of treatment in both studies, the majority of patients achieved sPGA 0/1 (88% and 84%, respectively), and PASI 90 in both studies reached 75% of patients receiving Skyrizi. According to the LIMMitless open extended study, after completion of ultIMMa-1 and –2 (based on LOCF analysis), the proportion of patients receiving Skyrizi up to 2.5 years (136 weeks) withholding PASI 90 and PASI 100 was 87% and 63%, respectively. One of the potential advantages of IL-23 inhibitors is also the long-term maintenance of the achieved effect after treatment cessation. During patient management in the course of randomized controlled trials of phase 3, data were obtained on the high safety of the drug and the absence of signifcant risks in relation to serious infections, cardiovascular events, malignant neoplasms. The drug is effective in case of insuffcient response to adalimumab, ustekinumab, secukinumab. The article presents two clinical cases of the use of risankizumab in patients of different ages with severe psoriasis, with ineffciency or intolerance to systemic therapy, as well as in connection with the eluding effect of previously conducted treatment methods. PASI 90/100 was achieved in all patients. No adverse events were observed.